



Contact: io.wens@kuleuven.be

KU LEUVEN


EORTC
European Organisation for Research
and Treatment of Cancer




Patient Preferences in Metastatic Prostate Cancer: A Qualitative Study Investigating Patients Trade-offs on Continuous versus Intermittent Intensified Androgen Deprivation Therapy

Io Wens¹, Ahu Alanya², Corneel Coens², Erik Briers³, Renée Bultijnck⁴, Mieke Van Hemelrijck⁵, Steven Joniau^{6,8}, Wouter Everaerts^{7,8}, Bertrand Tombal^{8,10}, Isabelle Huys¹


Background and objectives




Methods



Descriptive Results



Patient-reported treatment side-effects (>= grade 3)



Subsequent patient interviews:

- Further in-depth assessment of most important QoL attributes
- Patient trade-offs between QoL and OS attributes for iADT therapy

Conclusion

The results from this interview study will provide insights into patients' assessment and trade-offs of QoL and OS related treatment attributes.

A subsequent quantitative patient preference survey (discrete choice experiment) will quantify patients' therapeutic preferences and trade-offs for continuous versus intermittent iADT.

Support the interpretation of the DE-ESCALATE trial (EORTC 2238)

List of Abbreviations

mHSPC: metastatic hormone sensitive prostate cancer; iADT: intensified androgen deprivation therapy; OS: Overall Survival QoL: Quality of Life; EORTC: European Organisation for Research & Treatment of cancer

Acknowledgments

This study is a collaborative research project between KU Leuven, UZ Leuven and the European Organisation for Research and Treatment of Cancer (EORTC).

→ Scan **QR-code** for abstract and full author affiliations.

